CNTY-106

CNTY-106 is an investigational allogeneic, off-the-shelf cell therapy being developed for the treatment of multiple myeloma. It is part of a multi-specific collaboration program between Century Therapeutics and Bristol Myers Squibb. While specific molecular targets and engineering details of CNTY-106 have not been publicly disclosed as of August 2025, it is likely to be an induced pluripotent stem cell (iPSC)-derived cell-based product, leveraging Century's proprietary iPSC and Allo-Evasion engineering technologies, and may incorporate features for immune evasion and tumor targeting analogous to other products in the Century pipeline[1][2][5].